Anal Canal Cancer in the US: Finally Has an Immunotherapy What FDA Approval of Zynyz in 2025 Mean for Patients?

</style><h2>What Is Squamous Cell Carcinoma of the Anal Canal?</h2><p>Squamous cell carcinoma of the anal canal (SCAC) is a malignancy arising from the epithelium of the anal canal. In the United States, its incidence is approximately 2.0 per 100,000, with about 10,000 new diagnoses annually — making it one of the more prevalent rare cancers. The primary cause is persistent infection with human papillomavirus (HPV, particularly HPV-16/18); high-risk groups include HIV-positive individuals, immunosuppressed patients, and those with a history of anal receptive intercourse. Early-stage anal canal cancer is highly curable with concurrent chemoradiotherapy (fluorouracil + mitomycin C), with 5-year survival rates exceeding 80%. However, once the disease progresses to unresectable locally advanced or metastatic disease, no effective systemic therapy existed for decades, leaving patients with a grim prognosis.</p><h2>The Limitations of Conventional Treatment for Anal Canal Cancer</h2><p>Prior to 2025, the only available systemic treatment for advanced or metastatic SCAC was platinum-based chemotherapy (carboplatin or cisplatin + paclitaxel), with a median overall survival of approximately 12 months and no approved targeted or immunotherapy options. Because of the disease's rarity, clinical expertise outside major oncology centers is limited, and management has historically borrowed from colorectal cancer protocols without accounting for the distinct biology of anal canal squamous cell carcinoma.</p><h2>Latest U.S. Treatment Advances in Anal Canal Cancer (2025)</h2><p>On May 15, 2025, the FDA formally approved <strong>retifanlimab-dlwr (Zynyz, Incyte Corporation)</strong>, making it the first and only FDA-approved immune checkpoint inhibitor (anti-PD-1) for advanced anal canal cancer — a historic breakthrough after decades with no systemic therapy approvals.</p><p>The FDA approved two indications: (1) in combination with carboplatin and paclitaxel for adults with previously untreated unresectable locally recurrent or metastatic SCAC (first-line); and (2) as monotherapy for adults whose disease progressed on or who are intolerant to platinum-based chemotherapy (second-line).</p><p>The approval was based on data from the Phase III POD1UM-303/InterAACT 2 trial: the combination arm achieved a median PFS of 9.3 months versus 7.4 months in the control arm; an ORR of 56% versus 44%; and a preliminary median OS of 29.2 months versus 23.0 months — representing the most significant survival benefit ever demonstrated in advanced anal canal cancer. The FDA also granted orphan drug designation, underscoring support for rare cancer drug development.</p><h2>Challenges for International Patients and U.S. Clinical Resources</h2><p>International patients with anal canal cancer face significant barriers: the disease's rarity means that dedicated multidisciplinary expertise is concentrated at a small number of specialized centers worldwide. Zynyz is currently approved only in the United States; regulatory approval in Europe and elsewhere is pending, and access through standard oncology channels outside the U.S. remains limited. For patients with advanced or recurrent SCAC, accessing U.S. care — either through on-site treatment or remote expert consultation — represents the most clinically meaningful path forward today.</p><p><strong>MD Anderson Cancer Center</strong>'s Colorectal Center is one of the highest-volume anal canal cancer programs in the United States, with a dedicated multidisciplinary team (gastrointestinal medical oncology, radiation oncology, and colorectal surgery) offering HPV-related molecular profiling and comprehensive immunotherapy management. The team has extensive experience managing patients with concurrent HIV infection — a clinically important subgroup in anal canal cancer.</p><p><strong>Memorial Sloan Kettering Cancer Center (MSK)</strong>'s GI oncology division is one of the most active anal canal cancer research centers nationally, having co-led foundational molecular studies of SCAC biology. MSK offers Zynyz-based regimens and is currently enrolling patients in next-generation immunotherapy combination trials for patients who have progressed on first-line therapy.</p><h2>Anal Canal Cancer FAQ</h2><p><strong>How does treatment differ between early-stage and advanced anal canal cancer?</strong></p><p>Early-stage (Stage I–III) anal canal cancer is treated with concurrent chemoradiotherapy (fluorouracil + mitomycin C + radiation), which preserves anal function and achieves long-term remission in over 80% of patients without surgery. Advanced (unresectable locally recurrent or metastatic) anal canal cancer previously had no effective systemic therapy; the 2025 approval of Zynyz (retifanlimab) plus chemotherapy now gives this group a standard immunotherapy option with a meaningfully extended median survival.</p><p><strong>Is Zynyz appropriate for all anal canal cancer patients?</strong></p><p>Zynyz is currently approved specifically for the squamous cell carcinoma (SCAC) histological subtype in unresectable locally recurrent or metastatic settings — or for patients who have progressed on or are intolerant to platinum chemotherapy. Eligibility requires staging imaging to confirm disease extent and screening for contraindications to immunotherapy (e.g., active autoimmune disease). Evaluation at a specialized center with experience in anal canal cancer is strongly recommended.</p><p><strong>What is the relationship between HIV and anal canal cancer?</strong></p><p>HIV-positive individuals have a 30–100-fold higher risk of developing SCAC compared to the general population, primarily because HIV-related immunosuppression prevents clearance of persistent HPV infection. Importantly, HIV-positive patients who are well-controlled on antiretroviral therapy can still receive immunotherapy including Zynyz; MD Anderson's specialized team has extensive experience managing anal canal cancer patients with concurrent HIV infection.</p><h2>Anal Canal Cancer: U.S. Treatment Pathways</h2><p><strong>Pathway 1 — Remote Second Opinion:</strong> International patients can submit medical records, pathology reports, imaging, and genomic test results to a top U.S. cancer center without traveling. A specialized attending physician will review the full case and issue a written treatment recommendation, typically within 2–4 weeks, at no need to leave home.</p><p><strong>Pathway 2 — On-Site Treatment in the U.S.:</strong> For patients who need targeted therapy, immunotherapy, clinical trials, or complex surgery at a leading U.S. center, Medebound Health coordinates the entire process — appointment scheduling, visa invitation letters, medical record translation, and on-site concierge support. Appointments are typically confirmed within 5–7 business days.</p><p><strong>Medebound Health</strong> is a New York-based, U.S.-licensed cross-border medical navigation company with 10 years of experience exclusively focused on connecting international patients — especially Asian families — with top U.S. medical institutions. Founded by a former Dean of New York Medical College and a Board Member of NewYork-Presbyterian Hospital, Medebound Health has served over 3,000 Asian families and is the contracted partner of China Ping An, Taihe, and Taikang insurance groups. Our team provides both remote second opinion coordination and full on-site treatment support, with appointment lead times of just 5–7 business days. <a href="https://www.medeboundhealth.com">Learn more</a></p><h2>Why Seek Treatment in the U.S.? How Medebound Health Can Help</h2><p>Anal canal cancer management is highly specialized, and Zynyz's approval represents the first meaningful systemic therapy breakthrough in decades. Medebound Health can rapidly connect patients with MD Anderson's or MSK's dedicated anal canal cancer teams, facilitate expert assessment of immunotherapy eligibility, and — where appropriate — arrange all aspects of on-site treatment at a U.S. center, from appointment scheduling and visa support to on-site concierge services.</p><h3>Click the <strong>"Consult Now"</strong> button below to get a personalized 1-on-1 consultation and case examples (available 24/7).</h3>